Andera Partners
2, place Rio de Janeiro, Paris, Île-de-France, 75008, France
Overview
Private banking and asset management for wealthy families and institutions.
Founded
1953
Deals · 12mo
10
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
HighLife | Sep 2026Led | $92 MOther Equity | |
Cyllene Therapeutics | Jul 2026Participated | $38 MSeries C | |
Rivermark Medical | May 2026Led | $20 MSeries D | |
Alveus Therapeutics | Mar 2026Led | $197 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
Alveus Therapeutics | Jan 2026Led | $160 MSeries A | |
Spiro Medical | Jan 2026Led | $67 MSeries A | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Artios Pharma | Nov 2025Participated | $115 MSeries D | |
Tubulis | Oct 2025Participated | $357 MSeries C | |
Bioptimus | Jan 2025Participated | $41 MOther Equity | |
FIRE1 | Jan 2025Participated | $120 MOther Equity | |
HighLife | Sep 2026Led | $92 MOther Equity | |
Cyllene Therapeutics | Jul 2026Participated | $38 MSeries C | |
Rivermark Medical | May 2026Led | $20 MSeries D | |
Alveus Therapeutics | Mar 2026Led | $197 MSeries A | |
Exciva | Jan 2026Participated | $60 MSeries B | |
Alveus Therapeutics | Jan 2026Led | $160 MSeries A | |
Spiro Medical | Jan 2026Led | $67 MSeries A | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Artios Pharma | Nov 2025Participated | $115 MSeries D | |
Tubulis | Oct 2025Participated | $357 MSeries C | |
Bioptimus | Jan 2025Participated | $41 MOther Equity | |
FIRE1 | Jan 2025Participated | $120 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 12 | 3 |
| Series B | 7 | 12 |
| Series C+ | 3 | 15 |
| Other Equity | 6 | 9 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Apr '18 | 3 |
| May '18 | 0 |
| Jun '18 | 2 |
| Jul '18 | 1 |
| Aug '18 | 2 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 2 |
| Feb '19 | 2 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 1 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 1 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 1 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 2 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 2 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 2 |
| Aug '21 | 1 |
| Sep '21 | 1 |
| Oct '21 | 1 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 2 |
| Mar '22 | 1 |
| Apr '22 | 0 |
| May '22 | 2 |
| Jun '22 | 2 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 3 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 3 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 1 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 1 |
| Jan '24 | 1 |
| Feb '24 | 1 |
| Mar '24 | 2 |
| Apr '24 | 0 |
| May '24 | 1 |
| Jun '24 | 0 |
| Jul '24 | 2 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 2 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 1 |
| Nov '25 | 1 |
| Dec '25 | 1 |
| Jan '26 | 3 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 62 |
| Hardware & Robotics | 3 |
| Manufacturing | 3 |
| Clean Energy & Sustainability | 3 |
| Consumer & Lifestyle | 2 |
| Marketing & Advertising | 1 |
| Enterprise Software | 1 |
| Fintech | 1 |
| AI & Machine Learning | 1 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 1 |
| $10M-$25M | 7 |
| $25M-$50M | 18 |
| $50M-$100M | 21 |
| $100M-$250M | 18 |
| $250M-$500M | 1 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 52 |
| United States | 14 |
| Israel | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| EQT Life Sciences (LSP) | 19 |
| Bpifrance | 11 |
| Sofinnova Partners | 11 |
| Kurma Partners | 10 |
| Omega Funds | 8 |
| Pfizer Ventures | 7 |
| Gimv | 6 |
| Novo Holdings | 6 |
| OrbiMed | 6 |
| RA Capital Management | 6 |
| Sectoral Asset Management | 6 |
| Bayern Kapital | 5 |
| BioMedPartners | 5 |
| Fund+ | 5 |
| High-Tech Grunderfonds | 5 |
| Invus | 5 |
| IP Group | 5 |
| M Ventures | 5 |
| Pontifax | 5 |
| Seventure Partners | 5 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 28 | 42% |
| Participating | 39 | 58% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 9 | 32% |
| Co-led | 19 | 68% |
Team
Deputy Chief Financial Officer
Chief Financial Officer
Founder and CEO
Investment Director
Analyst
Partner
Associate
Director Investor Relations
Honorary Vice Chairman